Literature DB >> 3532920

A rapid HPLC method for monitoring plasma levels of caffeine and theophylline using solid phase extraction columns.

C E Pickard, A D Stewart, R Hartley, M D Lucock.   

Abstract

A simple HPLC method for the determination of caffeine and theophylline in plasma is described. Separation of theobromine, paraxanthine, theophylline, beta-hydroxyethyltheophylline and caffeine is obtained using a mobile phase of 1% acetic acid/methanol (83:17, v/v) and a Waters Associates NOVA-PAK C18 column protected by a Guard-PAK precolumn module containing a Guard-PAK CN cartridge. Rapid sample preparation is achieved by solid-phase extraction columns (Bond-Elut C18, 1 mL capacity) which provide excellent recovery values for both drugs. The cost per sample using this approach can be minimised by column regeneration and re-use. Results obtained for theophylline are in good agreement with values determined by other techniques.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3532920     DOI: 10.1177/000456328602300410

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  6 in total

1.  Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.

Authors:  Janne T Backman; Marika T Granfors; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2006-04-27       Impact factor: 2.953

2.  Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.

Authors:  Janne T Backman; Marjo J Karjalainen; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

3.  Acute effect of low dose theophylline on the circulatory disturbances of cirrhosis.

Authors:  E H Forrest; I A Bouchier; P C Hayes
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

4.  Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.

Authors:  Janne T Backman; Marika T Schröder; Pertti J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2007-10-23       Impact factor: 2.953

5.  Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.

Authors:  Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2007-07-06       Impact factor: 2.953

6.  Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo.

Authors:  Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2008-01-16       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.